24/7 Market News Snapshot 16 December, 2024 – Cardio Diagnostics Holdings Inc. Common stock (NASDAQ:CDIO)

December 16, 2024

DENVER, Colo., 16 December, 2024 (247marketnews.com) – (NASDAQ:CDIO) are discussed in this article.
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) is experiencing a notable upward momentum in the stock market, currently trading at $1.405, marking an 11.51% increase from the previous close of $1.260. This surge in trading volume, with 3.03 million shares exchanged, suggests heightened investor interest and positive sentiment surrounding the company. Analysts recommend monitoring technical indicators such as moving averages and relative strength index (RSI) for insights on future support and resistance levels. Should the bullish trend persist, CDIO may approach higher resistance points, positioning it as a potential growth opportunity for investors in the healthcare sector.

In addition to its market performance, Cardio Diagnostics has reached a significant milestone with the recent announcement of final pricing determinations from the Centers for Medicare & Medicaid Services (CMS) for its advanced tests, PrecisionCHD and Epi+Gen CHD. Effective for claims dating from January 1, 2025, this determination will enable Medicare contractors to establish pricing based on actual costs presented by the company. Dr. Meesha Dogan, CEO and Co-Founder of Cardio Diagnostics, emphasized that this decision is pivotal in enhancing risk assessment, diagnosis, management, and monitoring of coronary heart disease (CHD) for Medicare beneficiaries.

With cardiovascular disease as the primary cause of death among older adults in the United States, the implications of these innovations are significant. The PrecisionCHD test harnesses cutting-edge AI algorithms to analyze genetic and epigenetic markers for early detection of CHD, while Epi+Gen CHD assesses the risk of future heart events. Supported by dedicated CPT Proprietary Laboratory Analysis (PLA) codes, these tests reaffirm Cardio Diagnostics’ commitment to advancing personalized treatment strategies and improving patient outcomes in cardiovascular care.

Related news for (CDIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.